Werewolf Therapeutics Valuation
| HOWL Stock | USD 2.00 0.03 1.52% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Werewolf Therapeutics maintains a prevalent Real Value of $4.54 per share. The last-minute price of the company is $2.0. Our model calculates the value of Werewolf Therapeutics from examining the company fundamentals such as Operating Margin of (19.55) %, return on asset of -0.26, and Shares Outstanding of 44.56 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Werewolf Therapeutics' valuation include:
Price Book 0.9972 | Enterprise Value 3.1 M | Enterprise Value Ebitda 0.5683 | Price Sales 26.322 | Enterprise Value Revenue 0.9088 |
Undervalued
Today
Please note that Werewolf Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Werewolf Therapeutics is based on 3 months time horizon. Increasing Werewolf Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Werewolf stock is determined by what a typical buyer is willing to pay for full or partial control of Werewolf Therapeutics. Since Werewolf Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Werewolf Stock. However, Werewolf Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0 | Real 4.54 | Target 12.2 | Hype 1.97 | Naive 2.69 |
The intrinsic value of Werewolf Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Werewolf Therapeutics' stock price.
Estimating the potential upside or downside of Werewolf Therapeutics helps investors to forecast how Werewolf stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Werewolf Therapeutics more accurately as focusing exclusively on Werewolf Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Werewolf Therapeutics' intrinsic value based on its ongoing forecasts of Werewolf Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Werewolf Therapeutics' closest peers.
Werewolf Therapeutics Cash |
|
Werewolf Valuation Trend
Knowing Werewolf Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Werewolf Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Werewolf Therapeutics Total Value Analysis
Werewolf Therapeutics is currently anticipated to have valuation of 3.08 M with market capitalization of 89.13 M, debt of 51.92 M, and cash on hands of 145.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Werewolf Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.08 M | 89.13 M | 51.92 M | 145.71 M |
Werewolf Therapeutics Investor Information
About 73.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Werewolf Therapeutics recorded a loss per share of 1.52. The entity had not issued any dividends in recent years. Based on the key indicators related to Werewolf Therapeutics' liquidity, profitability, solvency, and operating efficiency, Werewolf Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Werewolf Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Werewolf Therapeutics has an asset utilization ratio of 11.41 percent. This suggests that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that Werewolf Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Werewolf Therapeutics Ownership Allocation
Werewolf Therapeutics retains a total of 44.56 Million outstanding shares. The majority of Werewolf Therapeutics outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Werewolf Therapeutics to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Werewolf Therapeutics. Please pay attention to any change in the institutional holdings of Werewolf Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Werewolf Therapeutics Profitability Analysis
The company reported the previous year's revenue of 19.94 M. Net Loss for the year was (37.37 M) with loss before overhead, payroll, taxes, and interest of (37.36 M).About Werewolf Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Werewolf Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Werewolf Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Werewolf Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Werewolf Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Werewolf Therapeutics. We calculate exposure to Werewolf Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Werewolf Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -19 M | -18 M | |
| Pretax Profit Margin | (1.87) | (1.97) | |
| Operating Profit Margin | (2.03) | (2.13) | |
| Net Loss | (1.87) | (1.97) | |
| Gross Profit Margin | (0.95) | (0.90) |
Werewolf Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Werewolf Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 35.6 M |
Werewolf Therapeutics Current Valuation Indicators
Werewolf Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Werewolf Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Werewolf Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Werewolf Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Werewolf Therapeutics' worth.When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.